EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer

Kento Kawasaki, Kazuhiro Noma, Takuya Kato, Toshiaki Ohara, Shunsuke Tanabe, Yasushige Takeda, Hijiri Matsumoto, Seitaro Nishimura, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki und 6 weitere

Cancer Immunology, Immunotherapy · 2023-11 · 72 (11) · 3787-3802

DOI: 10.1007/s00262-023-03531-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 05.09.2023. Verfasst von Kento Kawasaki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, …. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Esophageal Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Okayama University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays a crucial role in tumor immunosuppression, while the cancer-associated fibroblasts (CAFs) have various tumor-promoting functions. To determine the advantage of immunotherapy, the relationship between the cancer cells and the CAFs was evaluated in terms of the PD-1/PD-L1 axis. Overall, 140 cases of esophageal cancer underwent an immunohistochemical analysis of the PD-L1 expression and its association with the expression of the α smooth muscle actin, fibroblast activation protein, CD8, and forkhead box P3 (FoxP3) positive cells. The relationship between the cancer cells and the CAFs was evaluated in vitro, and the effect of the anti-PD-L1 antibody was evaluated using a syngeneic mouse model. A survival analysis showed that the PD-L1 + CAF group had worse survival than the PD-L1 - group. In vitro and in vivo, direct interaction between the cancer cells and the CAFs showed a mutually upregulated PD-L1 expression. In vivo, the anti-PD-L1 antibody increased the number of dead CAFs and cancer cells, resulting in increased CD8 + T cells and decreased FoxP3 + regulatory T cells. We demonstrated that the PD-L1-expressing CAFs lead to poor outcomes in patients with esophageal cancer. The cancer cells and the CAFs mutually enhanced the PD-L1 expression and induced tumor immunosuppression. Therefore, the PD-L1-expressing CAFs may be good target s for cancer therapy, inhibiting tumor progression and improving host tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsEsophageal NeoplasmsAnimalsMiceHumansB7-H1 AntigenCD8-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorImmunosuppression TherapyForkhead Transcription FactorsTumor Microenvironment

Stichwörter der Autor:innen

Cancer-associated fibroblastsEsophageal cancerImmune checkpoint inhibitorsProgram cell death ligand 1Programmed cell death 1

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorForkhead Transcription Factors

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. knoma@md.okayama-u.ac.jp.
  • Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Okayama University

Zitieren

APA

Kawasaki, K., Noma, K., Kato, T., Ohara, T., Tanabe, S., Takeda, Y., Matsumoto, H., Nishimura, S., Kunitomo, T., Akai, M., Kobayashi, T., Nishiwaki, N., Kashima, H., Maeda, N., Kikuchi, S., Tazawa, H., Shirakawa, Y., & Fujiwara, T. (2023). PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. Cancer Immunology, Immunotherapy, 72(11), 3787-3802. https://doi.org/10.1007/s00262-023-03531-2

Vancouver

Kawasaki K, Noma K, Kato T, Ohara T, Tanabe S, Takeda Y, et al. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. Cancer Immunology, Immunotherapy. 2023;72(11):3787-3802. doi:10.1007/s00262-023-03531-2

BibTeX
@article{Kawasaki2023,
  author = {Kawasaki, Kento and Noma, Kazuhiro and Kato, Takuya and Ohara, Toshiaki and Tanabe, Shunsuke and Takeda, Yasushige and Matsumoto, Hijiri and Nishimura, Seitaro and Kunitomo, Tomoyoshi and Akai, Masaaki and Kobayashi, Teruki and Nishiwaki, Noriyuki and Kashima, Hajime and Maeda, Naoaki and Kikuchi, Satoru and Tazawa, Hiroshi and Shirakawa, Yasuhiro and Fujiwara, Toshiyoshi},
  title = {PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {11},
  pages = {3787--3802},
  doi = {10.1007/s00262-023-03531-2}
}
Kostenlos starten →